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AbstrAct
background: The objective of the study was to dosimetrically compare the intensity-modulated-arc-therapy (IMaT), cyber-
Knife therapy (cK), single fraction interstitial high-dose-rate (hDr) and low-dose-rate (LDr) brachytherapy (BT) in low-risk 
prostate cancer.
Materials and methods: Treatment plans of ten patients treated with cK were selected and additional plans using IMaT, hDr 
and LDr BT were created on the same cT images. The prescribed dose was 2.5/70 Gy in IMaT, 8/40 Gy in cK, 21 Gy in hDr and 
145 Gy in LDr BT to the prostate gland. eQD2 dose-volume parameters were calculated for each technique and compared.
results: eQD2 total dose of the prostate was significantly lower with IMaT and cK than with hDr and LDr BT, D90 was 79.5 
Gy, 116.4 Gy, 169.2 Gy and 157.9 Gy (p < 0.001). however, teletherapy plans were more conformal than BT, cOIN was 0.84, 0.82, 
0.76 and 0.76 (p < 0.001), respectively. The D2 to the rectum and bladder were lower with hDr BT than with IMaT, cK and LDr 
BT, it was 66.7 Gy, 68.1 Gy, 36.0 Gy and 68.0 Gy (p = 0.0427), and 68.4 Gy, 78.9 Gy, 51.4 Gy and 70.3 Gy (p = 0.0091) in IMaT, cK, 
hDr and LDr BT plans, while D0.1 to the urethra was lower with both IMaT and cK than with BTs: 79.9 Gy, 88.0 Gy, 132.7 Gy and 
170.6 Gy (p < 0.001). D2 to the hips was higher with IMaT and cK, than with BTs: 13.4 Gy, 20.7 Gy, 0.4 Gy and 1.5 Gy (p < 0.001), 
while D2 to the sigmoid, bowel bag, testicles and penile bulb was higher with cK than with the other techniques.
conclusions: hDr monotherapy yields the most advantageous dosimetrical plans, except for the dose to the urethra, where 
IMaT seems to be the optimal modality in the radiotherapy of low-risk prostate cancer.
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Prostate cancer is the second most common can-
cer in men worldwide and the fourth most com-
monly occurring cancer overall. There were 1.3 mil-
lion new cases in 2019. It is estimated that 33,000 
deaths from this disease will occur this year [1]. The 
standard of care in the curative treatment of low- 
and selected intermediate-risk prostate cancer is 
external beam radiotherapy with intensity-modu-
lated arc therapy (IMAT) or with CyberKnife (CK) 
technique or interstitial high-dose-rate (HDR) or 
low-dose-rate (LDR) brachytherapy (BT) [2].
Since the α/β value of prostate tumour is low, 
dose escalation has an essential role in the devel-
opment of all radiotherapy modalities [3–5]. The 
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more complex the techniques, the more capable 
they are of escalating the dose to the tumour, while 
sparing the organs at risk (OARs). The IMAT tech-
nique results improved OAR sparing with accept-
able planning target volume (PTV) coverage [6]. 
Stereotactic radiotherapy with CyberKnife dem-
onstrated favourable tumour control, better patient 
reported quality of life and lower levels of toxicity 
[7]. The use of BT, as a boost, has been linked with 
improved biochemical progression free and overall 
survival [8, 9]. What is more, modern LDR mono-
therapy approach results in improved quality of life, 
as a consequence of lower acute urinary and rectal 
toxicity [11], with the dose coverage of the target 
volume (D90, the minimum dose delivered to 90% 
of the prostate) correlating with local tumour con-
trol [11], and the dose of the most exposed part of 
the OARs with normal tissue toxicity [12].
Despite the wide-spread application of these 
state-of-the-art techniques, no detailed analysis of 
all of these treatment techniques exists. Leszczyński 
et al. compared the dose distributions of intensity 
modulated prostate radiotherapy versus the IMAT 
technique [13]. Yang et al. investigated the dosimet-
ric differences among IMAT, HDR and LDT BT for 
10 patients, but HDR BT was not a single fraction 
monotherapy in their study [14]. Andrzejewski et 
al. studied the feasibility of dominant intraprostatic 
lesion (DIL) boosting using IMAT, proton therapy 
or HDR BT for 12 patients [15]. Georg et al. exam-
ined the optimal radiotherapy technique among 
IMAT, proton-, carbon-ion therapy and HDR or 
LDR BT, but HDR BT was not a single fraction 
monotherapy for the 10 studied patients [2]. Mor-
ton et al. studied HDR and LDR BT techniques 
against IMAT external beam therapy [16]. Fuller et 
al. dosimetrically compared CK and HDR BT plans 
for their first 10 patients treated with CK, but not all 
of the OARs relevant to CK treatment were evalu-
ated [17]. King examined HDR versus LDR BT as 
monotherapy and boost in a radiobiological model 
[18]. Skowronek made a practical comparison be-
tween HDR and LDR prostate BT [19].
At our institute, all of the four widely used treat-
ment techniques are available. To take the advan-
tage of this situation, the aim of the present study is 
a detailed dosimetric comparison of intensity-mod-
ulated arc therapy, CyberKnife therapy, interstitial 
high-dose-rate and low-dose-rate brachytherapy, as 
monotherapy in low-risk prostate cancer.
Materials and methods
Ten CK plans of patients with organ confined 
prostate cancer treated at our institute were includ-
ed in this study. Selection criteria for treatment 
were the following: PSA < 15 ng/mL and/or GS ≤ 7 
and/or Stage T ≤ 2c [20].
CK treatments were performed with non-co-
planar fields using CyberKnife M6 linear accelera-
tor (Accuray, Sunnyvale, CA, USA). Gold fiducial 
markers were implanted into the prostate gland 
to guide the placement of radiation beams during 
treatment. The CTV was extended by an isotropic 
3 mm margin, 8 Gy was delivered to this prostate 
PTV in each fraction according to an ongoing 
phase II prospective trial in our institute. A total 
of 5 fractions (total dose 40 Gy) were given every 
second working day. For treatment planning Ac-
curay Precision 1.1 treatment planning system 
(TPS) (Accuray, Sunnyvale, CA, USA) was used. 
The dose was prescribed to the 80−85% isodoses 
(Fig 1B). The relative volume of the PTV receiv-
ing at least the prescribed dose (V100) had to 
be at least 95%. The detailed description of our 
treatment method can be found in our previous 
publication [21].
On the CT series made for CK treatment plan-
ning, additional plans using IMAT, HDR and 
LDR BT were created using the same contour set. 
Where urethra was not identifiable on CT im-
ages, it was contoured between the bladder and 
the penile channel using a 15 mm pearl. IMAT 
plans were made in Eclipse v13.7 TPS (Varian 
Medical Systems, Palo Alto, USA) with a beam 
energy of 10 MV using 2 full arcs (Fig. 1A). CTV 
was extended using an isotropic 5 mm margin. 
The prescribed dose was 70 Gy, the dose of the 
daily fractions was 2.5 Gy for the PTV [22]. The 
protocol of our PROMOBRA study was applied 
for treatment planning in both HDR and LDR 
BT plans [23]. The prescribed dose in HDR BT 
was 21 Gy (V100 ≥ 95%) to the CTV of the CK 
plan, as the BT PTV, in a single treatment fraction 
using Ir-192 radioactive source. HIPO method 
was used to optimize the plans in the Oncentra 
Prostate v3.1 TPS (Elekta Brachytherapy, Veen-
dendaal, The Netherlands) (Fig. 1C). In LDR BT 
the prescribed dose was 145 Gy (V100 ≥ 95%) 
to the same CTV. IPSA optimisation method in 
the Oncentra Prostate v3.1 TPS (Elekta Brachy-
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therapy, Veendendaal, The Netherlands) was used 
to calculate the virtual positions of the I-125 iso-
topes (Fig. 1D). The detailed description of our 
treatment method can be found in our previous 
publications [24–27].
The equivalent dose given in 2 Gy fractions 
(EQD2) was calculated for each technique using 
the linear-quadratic radiobiological model [28, 29]. 
The α/β of prostate was assumed 1.5 Gy, while for 
OARs 3 Gy was used [30, 31]. 1 year was estimated 
in LDR BT as overall treatment time, as during this 
time 89% of the prescribed dose is delivered. The 
following dose-volume parameters were used for 
quantitative evaluation of plans:
• D90: the minimum dose delivered to 90% of 
PTV (Gy);
• COIN: conformal index [32];
• D0.1(x), D2(x): the minimal dose of the most ex-
posed 0.1 and 2 cm3 of the critical organ x (Gy),
where x: rectum (r), urethra (u), bladder (b), hips 
(h), sigmoid (s), bowel bag (bb), testicles (t) and pe-
nile bulb (p).
Friedman ANOVA and Fisher-LSD (Least Sig-
nificant Difference) post-hoc tests were used (Sta-
Figure 1. axial cT slide (left) and 3D reconstruction (right) of a prostate intensity-modulated arc therapy (A), cyberKnife (b), 
an interstitial high-dose-rate prostate brachytherapy (c) and an interstitial low-dose-rate prostate brachytherapy plan (D). 
red: prostate, yellow: prostatic urethra, light green: bladder, brown: rectum, dark brown: sigmoid, khaki: bowel bag, slate 
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tistica 12.5, StatSoft, Tulsa, OK, USA) to compare 
EQD2 dose-volume parameters of IMAT, CK, HDR 
and LDR BT techniques.
results
The mean volume of the PTV was 105.7 cm3 
(42.2–189.3 cm3) in IMAT, 85.5 cm3 (31.5–159.2 
cm3) in the CK and 61.8 cm3 (19.8–126.2 cm3) in 
both BT plans (which is equal to the original CTV) 
on average. We found that EQD2 total dose of the 
prostate was significantly lower with IMAT and 
CK than with HDR and LDR BT, D90 was 79.5 Gy, 
116.4 Gy, 169.2 Gy and 157.9 Gy (p < 0.001). How-
ever, IMAT and CK plans were more conformal 
than BT plans, COIN were 0.84, 0.82, 0.76 and 0.76 
(p < 0.001).
In our comparison, the D2 to the rectum and 
bladder were lower with HDR BT than with IMAT, 
CK and LDR BT, it was 66.7 Gy, 68.1 Gy, 36.0 Gy 
and 68.0 Gy (p = 0.0427), and 68.4 Gy, 78.9 Gy, 51.4 
Gy and 70.3 Gy (p = 0.0091) in IMAT, CK, HDR 
and LDR BT plans, while D0.1 to the urethra was 
lower with both IMAT and CK than with both BT 
modalities: 79.9 Gy, 88.0 Gy, 132.7 Gy and 170.6 
Gy (p < 0.001), respectively. D2 to the hips was 
higher with IMAT and CK, than with BTs: 13.4 
Gy, 20.7 Gy, 0.4 Gy and 1.5 Gy (p < 0.001), while 
D2 was higher to other organs with CK, than with 
the other techniques: 1.1 Gy, 17.9 Gy, 0.8 Gy and 
2.8 Gy (p < 0.001) for the sigmoid; 0.9 Gy, 11.2 Gy, 
0.7 Gy and 0.8 Gy (p < 0.001) for the bowel bag; 
0.4 Gy, 20.7 Gy, 0.6 Gy and 4.2 Gy (p = 0.0017) for 
the testicles; and 4.9 Gy, 10.3 Gy, 1.7 Gy and 3.2 
Gy (p = 0.0057) for the penile bulb in IMAT, CK, 
HDR and LDR BT plans. The detailed results can be 
found in Table 1.
Discussion
Dose escalation has a fundamental role in the 
radiotherapy of low- and selected intermediate-risk 
prostate cancer [3–5]. Several high-tech telether-
apy and BT techniques are widely used, such as 
image-guided and intensity-modulated teletherapy, 
arc therapy, stereotactic radiotherapy with linear 
accelerators or CyberKnife and interstitial HDR 
or LDR BT [2, 3, 6–9, 11, 12]. In the present study, 
all of the four widely used radiotherapy techniques 
(IMAT, CK, HDR and LDR BT) were compared 
dosimetrically using the linear-quadratic radiobio-
logical model.
Although these techniques rapidly developed 
parallelly, the dosimetrical differences were con-
table 1. Mean eQD2 total doses of intensity-modulated arc therapy (IMaT), cyberKnife (cK), high-dose-rate (hDr) and low-
-dose-rate (LDr) brachytherapy of prostate cancer. D90: the minimum dose delivered to 90% of prostate, cOIN: conformal 
index, D0.1(x), D2(x): the minimal dose of the most exposed 0.1 and 2 cm
3 of ‘x’ organ at risk, where x are rectum (r), urethra (u), 
bladder (b), hips (h), sigmoid (s), bowel bag (bb), testicles (t) and penile bulb (p). *Friedman aNOVa **Fisher-LsD post-hoc test
EQD2 IMAT CK HDR LDR p* **post hoc
D90 [Gy] 79.5 116.4 169.2 157.9 < 0.001 IMaT, cK
cOIN 0.84 0.82 0.76 0.76 < 0.001 IMaT-LDr, hDr
D0.1(r) [Gy] 86.4 80.0 55.3 93.5 0.0280 hDr, LDr
D2(r) [Gy] 66.7 68.1 36.0 68.0 0.0427 hDr
D0.1(u) [Gy] 79.9 88.0 132.7 170.6 < 0.001 all
D2(b) [Gy] 68.4 78.9 51.4 70.3 0.0091 hDr
D0.1(h) [Gy] 17.3 26.5 0.6 2.1 < 0.001 IMaT, cK
D2(h) [Gy] 13.4 20.7 0.4 1.5 < 0.001 IMaT, cK
D0.1(s) [Gy] 1.3 20.7 0.9 3.8 < 0.001 cK
D2(s) [Gy] 1.1 17.9 0.8 2.8 < 0.001 cK
D0.1(bb) [Gy] 1.1 12.1 1.1 1.3 < 0.001 cK
D2(bb) [Gy] 0.9 11.2 0.7 0.8 < 0.001 cK
D0.1(t) [Gy] 0.4 23.0 0.7 4.7 0.0006 cK, LDr
D2(t) [Gy] 0.4 20.7 0.6 4.2 0.0017 cK, LDr
D0.1(p) [Gy] 15.2 23.7 3.2 5.0 0.0014 IMaT, cK
D2(p) [Gy] 4.9 10.3 1.7 3.2 0.0057 IMaT, cK
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spicuous from the beginning. Leszczyński et al. 
have pointed out that the treatment delivery time 
is significantly reduced using the IMAT technique 
compared to intensity-modulated radiotherapy 
[13]. Yang et al. [14] concluded that HDR and LDR 
BT significantly reduce the dose to the rectum, 
bladder and femoral heads compared with IMAT. 
The mean EQD2 dose to the urethra was 80.3 Gy in 
IMAT, 70.2 Gy in HDR and 104.9 Gy in their LDR 
BT plans. They stated that for localised prostate 
cancer, HDR BT provides the advantage in sparing 
the urethra compared with IMAT and LDR; how-
ever, HDR BT was not a single-fraction treatment 
in this study. Our results are not in agreement with 
this, the EQD2 dose to the urethra was the lowest 
in the IMAT plans, D0.1 was 79.9 Gy. It was higher, 
88.0 Gy, with the CK technique, while still higher 
using HDR or LDR BT: 132.7 Gy and 170.6 Gy 
(all of the differences are significant). However, it 
has to be mentioned, that the relative D0.1 dose to 
the urethra — in proportion to the EQD2 D90 
dose — was 100.5% in IMAT, 75.6% in CK, 78.4% 
in HDR and 108.0% in the LDR plans. In terms 
of the other OARs sparing, HDR resulted in the 
lowest dose. This difference between the studies 
can be explained by the different fractionation and 
prescribed dose. Yang et al. used 78 Gy physical 
dose in 39 fractions in IMAT, 34 Gy in 4 fractions 
in HDR and 145 Gy in 1 fraction in LDR BT plans 
and calculated only mean dose of the OARs instead 
of volumetric doses.
Andrzejewski et al. studied the feasibility of DIL 
boosting and concluded that higher boost doses 
were achieved using proton therapy compared to 
IMAT, keeping doses of major OARs at similar lev-
els, but HDR BT was superior to IMAT and proton 
therapy, both in terms of OAR sparing and boosting 
of the DIL [15]. EQD2 D50 to DIL were 110.7 Gy, 
114.2 Gy and 150.1 Gy in IMAT, proton therapy 
and HDR BT plans, while the mean dose of the 
rectal wall was 30.5 Gy, 16.7 Gy and 9.5 Gy, and the 
mean dose to the bladder wall were 21.0 Gy, 15.6 
Gy and 6.3 Gy, respectively. Georg et al. examined 
the optimal radiotherapy technique in the radio-
therapy of localised prostate cancer and stated that 
HDR and LDR BT techniques were clearly superior 
in terms of the bladder and rectal wall sparing, in 
contrast with IMAT, proton- and carbon-ion ther-
apy, with the lowest values for HDR BT [2]. How-
ever, they did not examine the dose to the urethra. 
Based on our comparison, also single fraction HDR 
monotherapy yields the most advantageous plans, 
except in terms of the dose to the urethra where 
IMAT proves to be the optimal modality.
Morton et al. investigated HDR BT against LDR 
BT and IMAT external beam therapy in a clinical 
point of view [16]. They concluded that HDR BT 
enables more consistent implant quality than LDR 
BT, with evidence of lower acute and late toxicity. 
Higher disease control rates are also reported with 
HDR monotherapy than with the IMAT technique. 
These clinical results are in good agreement with 
our dosimetrical results. HDR BT resulted in the 
most optimal treatment plans in terms of both dose 
coverage of the prostate and the dose to OARs, ex-
cept for the urethra.
Fuller et al. pointed out that urethra dose is lower 
for virtual CK than for virtual HDR BT plans, sug-
gesting that the CK technique may more effectively 
limit urethra dose [17]. Bladder maximum point 
doses were higher with HDR BT, but bladder dose 
fall-off beyond the maximum dose region was more 
rapid with this technique than using CK therapy. 
Our study added a new result to this conclusion, 
specifically using IMAT the dose to the urethra is 
lower than CK and both BT modalities.
Based on the radiobiological examination of 
King, HDR and LDR BT achieve superior tumour 
control when compared with IMAT using conven-
tional doses, and HDR BT might achieve superior 
tumour control compared with LDR [18]. This re-
sult supports the clinical evidence for equivalent 
outcomes in localised prostate cancer with either 
HDR or LDR BT. However, HDR BT dose escalation 
regimens might be able to achieve higher biologi-
cal effectiveness and hence improved outcomes in 
contrast to IMAT. In the same manner, in our plans, 
higher EQD2 total doses can be reached to the pros-
tate with BT techniques than with external radiation 
techniques, and this dose is the lowest using IMAT.
Skowronek [19] demonstrated that all available 
clinical data regarding HDR and LDR BT suggests 
that they are equally effective, stage for stage, in 
providing high tumour control rates. The important 
difference in dosimetric control is that HDR doses 
can be escalated safely providing such a flexibility 
that does not exist for LDR BT. Our examination 
also gave one vote for HDR BT, as the most ap-
propriate technique of dose escalation in prostate 
radiotherapy.
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It has to be mentioned, that in our study, the 
virtual BT plans were made on the planning CT 
of the CK, and this anatomy is not optimal for BT 
planning. Furthermore, the EQD2 prescribed dose 
was higher in both BT techniques than in the IMAT 
and CK plans, as the recommended, clinically used 
fractionation was applied in our plans. Despite that, 
HDR BT proved to be the optimal choice in the 
aspects of sparing most of the OARs beside dose 
coverage of the prostate. LDR BT resulted in higher 
dose to the OARs with approximately equivalent 
prescribed dose to the prostate.
conclusions
Using single fraction HDR and LDR BT, total 
dose of the prostate is higher than with IMAT or 
CK techniques and, accordingly, dose to the ure-
thra is also higher with both BT modalities us-
ing the recommended fractionation scheme. Dose 
to the rectum and bladder is lower with HDR BT 
than with IMAT, CK and LDR BT, while dose to 
the sigmoid, bowel bag, testicles and penile bulb 
are higher with CK than using the other examined 
techniques. Overall, HDR monotherapy yields the 
most advantageous plans in the radiotherapy of 
low- and intermediate risk prostate cancer, except 
in terms of the dose to the urethra where IMAT 
proves to be the optimal modality.
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